AbbVie (ABBV) announced a new $380M investment to build two new active pharmaceutical ingredient manufacturing facilities at its current North Chicago, Illinois, campus. These new facilities will integrate advanced manufacturing technologies with artificial intelligence to support the production of AbbVie’s next-generation neuroscience and obesity medications. Construction will begin in spring 2026, with both new facilities expected to be fully operational in 2029. To support these new facilities, AbbVie plans to hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Ideaya Biosciences appoints Theodora Ross as chief development officer
- AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
- Barclays Bank (BCS) Names Four Pharma Stocks to Buy Now
- FDA approves AbbVie venclexta, acalabrutinib supplemental new drug application
- AbbVie initiated with an Overweight at Barclays